PBHNYSEPharmaceutical PreparationsFiscal year ends March 31
Prestige Consumer Healthcare Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$49.71−0.21 (-0.42%)
Close on Oct 19, 2026
- Market cap
- $2.37B
- P/E (TTM)
- 13.9
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
54.7%−3.3 pts over 5 years
Operating margin
28.4%−3.1 pts over 5 years
Net margin
17.5%+0.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -4.3% | -1.2% | +2.9% | +3.0% | |
| Gross profit | -6.1% | -1.6% | +1.7% | +2.5% | |
| Operating income | -8.1% | – | +0.8% | +1.7% | |
| Net income | -11.3% | – | +2.9% | +6.7% | |
| EPS, diluted | -8.9% | – | +3.8% | +7.6% | |
| Free cash flow | +1.3% | +3.6% | +2.9% | +3.6% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | 8.9% | 13.0% | 10.2% | |
| Return on assets | 2.0% | 4.7% | 5.5% | |
| Current ratio | 2.06 | 2.21 | 3.57 | |
| Debt to equity | 2.67 | 1.09 | 0.53 | |
| Net debt to EBITDA | 9.30× | 4.42× | 2.73× | |
| Interest coverage | 2.2× | 3.6× | – | |
| Inventory turnover | 3.7× | 3.4× | 3.2× | |
| Capex to revenue | 0.3% | 2.4% | 1.0% | |
| Diluted shares | 53M | 51M | 49M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Prestige Consumer Healthcare generated $1.25B from operations and spent $329.17M on capital expenditure, dividends and share buybacks. 14% of that went back into the business.
Generated
$1.25B
Used
$329.17M
Capital expenditure$46.38M14%Dividends$00%Share buybacks$282.79M86%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin17.5%
×Asset turnover0.32×
×Equity multiplier1.85×
=Return on equity, FY202610.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | 17.5% | 0.32× | 1.85× | 10.2% |
| FY2025 | 18.9% | 0.34× | 1.93× | 12.3% |
| FY2024 | 18.6% | 0.34× | 2.15× | 13.5% |
| FY2023 | -7.3% | 0.32× | 2.32× | -5.4% |
| FY2022 | 18.9% | 0.31× | 2.42× | 14.0% |
| FY2021 | 17.5% | 0.27× | 2.75× | 13.0% |
| FY2020 | 14.8% | 0.28× | 3.07× | 12.6% |
| FY2019 | -3.7% | 0.27× | 3.17× | -3.1% |
| FY2018 | 32.6% | 0.27× | 3.83× | 33.9% |
| FY2017 | 7.9% | 0.26× | 4.38× | 8.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
4of 8 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero$190.30M
- Cash generatingOperating cash flow above zero$257.63M
- Return on assets improvedROA up on the prior year6.5% → 5.6%
- Earnings backed by cashOperating cash flow above net income$257.63M vs $190.30M
- Less leverageLong-term debt to assets fell– → 28.4%
- Better liquidityCurrent ratio rose4.20 → 3.57
- No dilutionShare count did not rise50M → 49M
- Gross margin improvedGross margin up on the prior year55.76% → 54.71%
- More efficientAsset turnover rose0.34 → 0.32